Table 2.

Procedural characteristics and clinical outcomes

Variables
Time from diagnosis to procedure, days, mean ±SD	1.6 ± 1.4
Initial anticoagulant
Unfractionated heparin	62 (56.4)
Low-molecular-weight heparin	41 (37.3)
PE location
Bilateral	110 (100)
Saddle and main arteries	56 (50.9)
Lobar and segmental	54 (49.1)
Segmental	—
Access-site
Common femoral vein	108 (98.2)
Jugular vein	2 (1.8)
Access-site complications
Major a	2 (1.8)
Minor	8 (7.3)
Total procedure duration time (min), mean ±SD	64.7 ± 22.0
Amount of blood loss, ml, mean ±SD	296.0 ± 79.2
Periprocedural ECMO use	3 (2.7)
Vena cava filter implantation	4 (3.6)
Conversion to open surgery	1 (0.9)
Length of hospitalization, days, mean ±SD	10 ± 6.8
Length of hospitalization after the procedure, days, mean ±SD	8 ± 5.6
Need for ICU stay	12 (10.9)
Anticoagulation at discharge	65 (59)
Direct oral anticoagulant	9 (8.2)
Vitamin K antagonist	20 (18.2)
Low-molecular-weight heparin None	4 (3.6)

No need for surgical or endovascular treatment.

Abbreviations: See Table 1. ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.